Psychiatry & Neurology Doctors in Silverdale, WA Accepting Medicare

7 Psychiatry & Neurology doctors found. Showing 1 - 7

Timothy Andrew Scearce, M.D. Psychiatry & Neurology - Neurology Medicare: Accepting Medicare Assignments Practice Location: 10452 Silverdale Way Nw, Silverdale, WA 98383 Phone: 360-307-7300

Dr. John D Gonsoulin, MD Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 9633 Levin Rd Nw Ste 103, Silverdale, WA 98383 Phone: 360-337-8200    Fax: 360-337-6956

William F. Hiltz, M.D. Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 7462 Nw Ioka Dr, Silverdale, WA 98383 Phone: 360-613-9894

Robert Scott Rubenstein, M.D. Psychiatry & Neurology - Clinical Neurophysiology Medicare: Accepting Medicare Assignments Practice Location: 2011 Nw Myhre Pl, Silverdale, WA 98383 Phone: 360-830-1605    Fax: 360-830-1693

Adam Michael Kusic, DO Psychiatry & Neurology - Psychiatry Medicare: Medicare Enrolled Practice Location: 1800 Nw Myhre Rd, Silverdale, WA 98383 Phone: 360-744-8800

Geary A. Heine, M.D, Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 9395 Linder Way Nw, Suite # 202, Silverdale, WA 98383 Phone: 360-307-7010    Fax: 360-307-9170

Eric T Lee, DO Psychiatry & Neurology - Neurology Medicare: Accepting Medicare Assignments Practice Location: 2011 Nw Myhre Pl, Silverdale, WA 98383 Phone: 360-830-1605    Fax: 360-830-1693

News Archive

New study shows team training of health care staff can reduce patient mortality by 15%

Team training of health care employees can reduce patient mortality by 15 percent, according to a new study from Rice University, the Johns Hopkins University School of Medicine, the University of Central Florida, the U.S. Department of Defense and the Michael E. DeBakey VA Medical Center.

Nimbus Discovery closes $24 million Series A financing

Nimbus Discovery LLC, a biopharmaceutical company using state-of-the-art computational technology to discover novel medicines against exciting but previously inaccessible disease targets, today announced the close of a $24M Series A financing.

MPM Capital leads Alnara Pharmaceuticals' $35M Series B venture capital financing

Alnara Pharmaceuticals, Inc., a pharmaceutical company developing non-systemic, orally-delivered protein therapeutics for the treatment of metabolic diseases, announced today that it has secured $35 million in Series B venture capital financing. The round was led by new investor MPM Capital, joined by current investors Third Rock Ventures, Frazier Healthcare and Bessemer Venture Partners. In conjunction with the MPM investment, managing director Ashley Dombkowski, Ph.D., will join Alnara's board of directors.

Despite reduced trauma cases during COVID-19 lockdown, gun violence remain a key problem

Philadelphia hospitals saw a drop in overall trauma cases once Pennsylvania enacted a COVID-19-related stay-at-home order in 2020, but gun violence remained a significant problem.

Porvair sciences introduce products for use in animal and plant genetics

Porvair Sciences will showcase two important technical breakthroughs at PAG XXV in San Diego (USA) from January 14-18, 2017.

Read more Medical News

› Verified 9 days ago